The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Latest NewsMORE >>

Patients with ROS1 fusion–positive non–small cell lung cancer had clinically meaningful and durable benefit across multiple doses of repotrectinib (TPX-0005), according to interim findings from the ongoing phase I/II TRIDENT-1 study, presented at the 19th World Conference on Lung Cancer.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.